Vanda Pharmaceuticals Inc. (VNDA)
VNDA Stock Price Chart
Explore Vanda Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze VNDA price movements and trends.
VNDA Company Profile
Discover essential business fundamentals and corporate details for Vanda Pharmaceuticals Inc. (VNDA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Apr 2006
Employees
368.00
Website
https://www.vandapharma.comCEO
Mihael H. Polymeropoulos
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
VNDA Financial Timeline
Browse a chronological timeline of Vanda Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.38.
Earnings released on 31 Jul 2025
EPS came in at -$0.46 falling short of the estimated -$0.34 by -35.29%, while revenue for the quarter reached $52.59M , missing expectations by -10.46%.
Earnings released on 7 May 2025
EPS came in at -$0.50 surpassing the estimated -$0.55 by +9.09%, while revenue for the quarter reached $50.04M , beating expectations by +10.87%.
Earnings released on 13 Feb 2025
EPS came in at -$0.08 surpassing the estimated -$0.14 by +42.86%, while revenue for the quarter reached $53.19M , beating expectations by +1.79%.
Earnings released on 6 Nov 2024
EPS came in at -$0.09 surpassing the estimated -$0.17 by +47.06%, while revenue for the quarter reached $47.65M , missing expectations by -3.05%.
Earnings released on 31 Jul 2024
EPS came in at -$0.08 surpassing the estimated -$0.21 by +61.90%, while revenue for the quarter reached $50.47M , missing expectations by -0.50%.
Earnings released on 8 May 2024
EPS came in at -$0.07 falling short of the estimated $0.05 by -240.00%, while revenue for the quarter reached $47.46M , missing expectations by -2.14%.
Earnings released on 7 Feb 2024
EPS came in at -$0.04 surpassing the estimated -$0.09 by +55.56%, while revenue for the quarter reached $45.27M , beating expectations by +22.35%.
Earnings released on 8 Nov 2023
EPS came in at $0.00 surpassing the estimated $0.00 by +100.00%, while revenue for the quarter reached $38.82M , missing expectations by -12.78%.
Earnings released on 27 Jul 2023
EPS came in at $0.03 surpassing the estimated -$0.13 by +123.08%, while revenue for the quarter reached $46.06M , missing expectations by -8.80%.
Earnings released on 3 May 2023
EPS came in at $0.06 , while revenue for the quarter reached $62.50M .
Earnings released on 8 Feb 2023
EPS came in at $0.12 surpassing the estimated $0.08 by +50.00%, while revenue for the quarter reached $64.48M , missing expectations by -4.61%.
Earnings released on 2 Nov 2022
EPS came in at $0.06 falling short of the estimated $0.09 by -33.33%, while revenue for the quarter reached $65.32M , missing expectations by -8.00%.
Earnings released on 3 Aug 2022
EPS came in at $0.05 falling short of the estimated $0.11 by -54.55%, while revenue for the quarter reached $64.39M , missing expectations by -3.90%.
Earnings released on 5 May 2022
EPS came in at -$0.11 falling short of the estimated -$0.01 by -1.00K%, while revenue for the quarter reached $60.19M , beating expectations by +3.78%.
Earnings released on 23 Feb 2022
EPS came in at $0.12 surpassing the estimated $0.09 by +33.33%, while revenue for the quarter reached $68.02M , missing expectations by -2.88%.
Earnings released on 3 Nov 2021
EPS came in at $0.14 falling short of the estimated $0.18 by -22.22%, while revenue for the quarter reached $70.10M , missing expectations by -6.54%.
Earnings released on 28 Jul 2021
EPS came in at $0.17 surpassing the estimated $0.14 by +21.43%, while revenue for the quarter reached $67.90M , missing expectations by -9.47%.
Earnings released on 5 May 2021
EPS came in at $0.15 matching the estimated $0.15, while revenue for the quarter reached $62.67M , missing expectations by -8.51%.
Earnings released on 10 Feb 2021
EPS came in at $0.15 surpassing the estimated $0.14 by +7.14%, while revenue for the quarter reached $67.65M , beating expectations by +7.69%.
Earnings released on 28 Oct 2020
EPS came in at $0.11 surpassing the estimated $0.10 by +10.00%, while revenue for the quarter reached $60.31M , missing expectations by -63.10%.
VNDA Stock Performance
Access detailed VNDA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.